Human HDAC2 , GenBank Accession No. NM_001527, full length with C-terminal His-tag, MW= 56 kDa, expressed in baculovirus expression system.

Q92769

histone deacetylase 2, HDAC-2

≥675 pmol/min/µg

25 mM of Tris-HCl , pH 8.0, 137 mM of NaCl, 2.7 mM of KCl, 1 mM of MgCl₂, 0.1 mg/ml BSA, 20 µM substrate , BPS catalog #: 50037, and HDAC2, at 37°C, 30 min. followed by incubation with HDAC developer (Catalog #50030) for 15 min at RT. Fluorescence intensity is measured at ex360/em460.

40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, 20% glycerol, 200 mM imidazole

Aqueous buffer solution

>6 months at -80°C.

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Yang,W.M. et al., Proc. Natl. Acad. Sci. U.S.A. 93 (23), 12845-12850 (1996).
2. Mungall, A.J. et al., Nature 425 (6960), 805-811 (2003).

Application References:
1. Exploration of some indole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents (2017)
2. An azumamide C analogue without the zinc-binding functionality (2017)
3. Impact of binding mechanism on selective inhibition of histone deacetylase isoforms (2017)
4. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif (2017)
5. Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation (2015)
6. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases (2015)
7. Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction (2015)
8. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy (2014)
9. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014)
10. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1 (2014)
11. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014)
12. Reassessing the effects of histone deacetylase inhibitors on hippocampal memory and cognitive aging (2014)
13. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11 (2014)
14. Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection (2014)
15. Class I HDAC imaging using [ (3)H]CI-994 autoradiography (2013)
16. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013)
17. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013)
18. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013)
19. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013)
20. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA (2013)
21. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp (2013)
22. Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E (2013

Avoid freeze/thaw cycles.

Deacetylase

Recombinant Protein